CDKN2A and head and neck cancer: In fact, almost 30 years ago, in the wake of works defining the inactivation of p16ink4a as a potential step towards cancerogenesis in some head and neck cancers [72,73], the first evidence of the loss of heterozygosity (LOH) at the 9p arm in a subset of laryngeal cancers in a variable percentage of LSCCs emerged [74,75].